🇺🇸 FDA
Pipeline program

Tideglusib

PHRI.TaRGET

Phase 2 small_molecule active

Quick answer

Tideglusib for Arrhythmogenic Cardiomyopathy is a Phase 2 program (small_molecule) at Rhythm Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Rhythm Pharmaceuticals Netherlands B.V.
Indication
Arrhythmogenic Cardiomyopathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials